Trade Tracker: Josh Brown buys Pfizer
Josh Brown, CEO at Ritholtz Wealth Management, joins CNBC's 'Halftime Report' to discuss his latest healthcare trade.
Will Pfizer's Stock Bounce Back in 2024?
Pfizer stock trades at a low multiple of its estimated future earnings. The company's COVID-19-related revenue declined sharply in recent quarters.
Pfizer Inc. (PFE) J.P. Morgan 42nd Annual Healthcare Conference (Transcript)
Pfizer Inc. (PFE) J.P. Morgan 42nd Annual Healthcare Conference (Transcript)
Pfizer to remain aggressive on obesity market after setback
Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Ex...
Pfizer: 50% Down From The Highs, Generous Dividend, And Robust Balance Sheet
Big pharma is one of the laggards and now rotational targets headed into 2024. Pfizer is one of the worst performers of the group, but also one of the oldest and most mature of the peer group. If t...
Pfizer shares downgraded as patent expirations loom
Pfizer Inc. shares PFE, were downgraded to market perform from outperform at TD Cowen on Thursday, as analysts see upcoming patent expirations and shaky confidence in the drugmaker's management clo...
Pfizer (PFE) Flat As Market Sinks: What You Should Know
Pfizer (PFE) closed the most recent trading day at $29.73, making no change from the previous trading session.
Vaccine Stock the Worst to Own in January, Historically
Pfizer Inc (NYSE:PFE) stock moved steadily lower in 2023, closing 11 out of 12 months lower, with March as the only gainer.
Pfizer: If You Missed The Pandemic Entry, Here's Another Chance
Pfizer remains a strong investment opportunity with a diverse product portfolio and solid financials despite a decline in revenue due to the end of the pandemic. The company has demonstrated resili...
Canada approves Pfizer's gene therapy for bleeding disorder
Pfizer said on Wednesday that Canada's health regulator approved its gene therapy for the treatment of a rare inherited bleeding disorder called hemophilia B.
Pfizer, big drugmakers expected to hike prices on at least 500 drugs in January
The expected price hikes come as the pharmaceutical industry gears up for the Biden Administration to publish significantly discounted prices for 10 high-cost drugs in September, and continues to c...
Could Pfizer Be a No-Brainer Stock to Buy Right Now, Even If Its COVID Sales Continue to Plunge?
Pfizer's COVID-19 product revenue is sinking. Even in a worst-case scenario, though, Pfizer's valuation is much cheaper than its peers.
The Pfizer Advantage: High Dividend Yield, JN.1 Variant, And Therapeutic Innovations
Pfizer is one of the largest American pharmaceutical companies, developing medicines and vaccines using cutting-edge technologies to save and improve the lives of millions worldwide. Pfizer's reven...
Pfizer (PFE) Surpasses Market Returns: Some Facts Worth Knowing
In the most recent trading session, Pfizer (PFE) closed at $28.61, indicating a +0.7% shift from the previous trading day.
Are Investors Overreacting to Pfizer's Underwhelming Forecast for 2024?
Pfizer is going to see its business slow down next year as the pandemic fades further. If not for its recent acquisition of Seagen, the company's top line would struggle even more in 2024.
Related Companies